Healio
Healio
an image of a hand in a blue medical glove holding a tube of blood with blood cells as the background

Take Homes in Benign Hematology
ByDavid Statman
Fact checked byMindy Valcarcel, MS

Read more

December 19, 2024
1 min watch
Save

VIDEO: ABCG2 inhibitor shows promising indicators for erythropoetic protoporphyria

ByDavid Statman
Fact checked byMindy Valcarcel, MS

In this video, Amy Dickey, MD, MSc, discusses a study presented at ASH Annual Meeting that examined the use of an ABCG2 inhibitor in patients with erythropoetic protoporphyria.

Dickey, an assistant professor at Massachusetts General Hospital, highlighted the study, which presented results in mice that she characterized as promising for its eventual use in humans.

“This inhibitor of ABCG2 that they've been looking at in mice has been able to improve symptoms in [erythropoetic protoporphyria] and improve liver disease, and they're working on developing that for people,” Dickey said.

Reference:

  • Shah B, et al. Abstract 11. Presented at: ASH Annual Meeting and Exposition; Dec. 7-10, 2024; San Diego.
Sources/Disclosures

Collapse
Source:

Healio Interviews

Disclosures: Dickey reports receiving research funding from Alnylam Pharmaceuticals and Mitsubishi Tanabe, and consulting for Recordati Pharmaceuticals.

Read more about

erythropoietic protoporphyria
 

Related Content